VOA News interviews Peter Small, senior program officer for tuberculosis (TB) at the Bill & Melinda Gates Foundation, about recent research developments and the global TB response. VOA writes, “Small … “Small says streamlining approval of effective drug regimens allows those who are infected to receive treatment sooner. But drugs are not the ultimate solution when addressing TB.” Small said, “I think the Holy Grail remains a vaccine. … We do need a vaccine to finish the job,” according to VOA. “As the world awaits a vaccine, research continues on new drugs that could be effective against multidrug-resistant and extensively drug-resistant types of TB,” the news service writes, adding, “Treating the millions of children and adults infected with TB may seem daunting,” but “the fact that the TB mortality rate has decreased 41 percent since 1990 gives hope for future progress and elimination of the disease” (Martin, 7/10).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.